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Efﬁcacy and safety of dovitinib in
pretreated advanced squamous
non-small cell lung cancer with
FGFR1 ampliﬁcation: A single-arm,
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Byoung Chul Cho2 1Samsung Medical Center, Seoul,
Korea, 2Yunsei University, Seoul, KoreaPurpose: FGFR1 ampliﬁcation is one of the most com-
mon potential driving oncogenes in squamous cell car-
cinoma (SCC), which accounts for 20% of non-small cell
lung cancer (NSCLC). This phase II study evaluated the
efﬁcacy and toxicity proﬁle of dovitinib, an orally active
ﬁbroblast growth factor receptor (FGFR) inhibitor, in
advanced lung SCC patients.
Experimental Design: Patients with histological
conﬁrmed advanced squamous cell NSCLC and previously
treated with at least one cytotoxic chemotherapy were
enrolled. All patients had FGFR1 gene ampliﬁcation more
than 5 copies by ﬂuorescent in situ hybridization (FISH).
Each 7-day treatment cycle consisted of dovitinib 500mg
orally administration on days 1 to 5 and 2 days off. Pri-
mary endpoint was overall response rate and secondary
endpoints included PFS, OS and toxicity. Exploratory
analysis for FGFR1-3 mRNA expression was performed.
The mRNA in situ hybridization (ISH) assay was per-
formed using the RNA scope 2.0 assay system and the
FGFR1 probe provided by Advanced Cell Diagnostics.
Results: All 26 patients were male with the median age
of 68 years (range, 52–80). Most patients were ever
smokers (96%) and had good ECOG (0-1) performance
status (85%). The median number of dovitinib treatment
cycles administered was 2.5 (range, 1-12). The overall
response rate (ORR) was 11.5% (95% CI, 0.8–23.8) and
disease control rate (DCR) was 50% (95% CI, 30.8–
69.2). There were 3 partial responses (PR) and 10 stable
diseases (SD). Duration of response in 3 patients who
achieved PR was 4.5þ, 5.1þ and 6.1 months, respec-
tively. After the median follow-up duration of 15.7
months (range, 1.2–25.6), the median overall survival
(OS) was 5.0 months (95% Conﬁdential Interval, 3.61–
6.39) and progression-free survival (PFS) was 2.9Journal of Thoracic Oncology Vol. 11 No. 2S: S16-S55months (95% CI, 1.54–4.26). The most common grade 3
or higher AEs suspected to be related to dovitinib
treatment were fatigue (19.2%), anorexia (11.5%), and
hyponatremia (11.5%) and 12 patients (46%) required
dose reduction of dovitinib. Further analysis for FGFR1
mRNA, only modest overlap (31.2%) of FGFR1 expres-
sion at the mRNA level with FGFR1 ampliﬁcation was
found. The expression of FGFR1 mRNA was not associ-
ated with degree of FGFR1 gene ampliﬁcation nor FGFR2
or FGFR3 mRNA expression.
Conclusion: Dovitinib treatment showed modest efﬁ-
cacy in advanced squamous cell lung cancer patients
with FGFR1 ampliﬁcation. Further studies to evaluate
other biomarkers correlated with the efﬁcacy of doviti-
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Lung cancers that harbor genomic ALK alterations are
clinically responsive to pharmacologic ALK inhibition.
Crizotinib, an orally available small-molecule inhibitor of
the ALK tyrosine kinase, was approved for the treatment
of ALKþ lung cancer patients. Unfortunately, as seen
with other tyrosine kinases inhibitors (TKIs) in clinical
use, most patients whose disease initially responds to
crizotinib eventually develop progressive disease. To
elucidate mechanisms of acquired resistance to ALK
TKIs, we established and characterized novel ALKþ cell
lines from patients with acquired resistance to ALK TKI
therapy. In particular, we developed a cell line (desig-
nated STM) from a patient with an EML4-ALK (E6;A20,
variant 3) fusion that developed acquired resistance to
crizotinib. Fluorescence in situ hybridization conﬁrmed
that the cell line retained the ALK rearrangement. STM
cells had decreased sensitivity to crizotinib and second-
generation ALK inhibitors, including ceritinib, alectinib,
and X-396. Morphologic changes were observed in this
patient-derived cell line, the tumor cells had a spindle
form, characteristic of the epithelial-mesenchymal tran-
sition (EMT). Loss of expression of the epithelial marker,
E-cadherin, was accompanied by strong expression of the
